Champions Oncology (CSBR) vs. Its Competitors Head to Head Comparison

Champions Oncology (NASDAQ:CSBR) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its peers? We will compare Champions Oncology to related companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, risk, profitability and earnings.

Volatility and Risk

Champions Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Champions Oncology’s peers have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.

Insider & Institutional Ownership

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 54.3% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 46.3% of Champions Oncology shares are owned by insiders. Comparatively, 15.2% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Champions Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Champions Oncology Competitors	-539.78%	77.25%	-13.56%

Earnings & Valuation

This table compares Champions Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Champions Oncology	$59.42 million	-$1.17 million	-59.62
Champions Oncology Competitors	$2.28 billion	$55.88 billion	-7.60

Champions Oncology’s peers have higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations for Champions Oncology and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1	0	0	0	1.00
Champions Oncology Competitors	957	3183	5516	178	2.50

As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.76%. Given Champions Oncology’s peers stronger consensus rating and higher possible upside, analysts clearly believe Champions Oncology has less favorable growth aspects than its peers.

Summary

Champions Oncology peers beat Champions Oncology on 10 of the 13 factors compared.

Champions Oncology Company Profile

Champions Oncology, Inc. is a life sciences company focused on precision oncology. It provides data, laboratory, and technology solutions designed to help biopharmaceutical companies and clinicians better understand cancer biology, evaluate potential therapies, and support more individualized treatment decisions. The company’s offerings include patient-derived tumor models, commonly known as TumorGraft models, which are created by implanting human tumor tissue into laboratory models to study drug responses.